BioTuesdays

Category - Markets

Pharming Group

HCW starts Pharming at buy

H.C. Wainwright launched coverage of  Pharming Group NV (AEX:PHARM) with a “buy” rating and €1.50 price target. The stock was recently quoted at €0.45. Pharming is focused on the development of protein therapeutics for...

Evotec

Roth ups Evotec price target to €16

Roth Capital Partners raised its price target for “buy-rated” Evotec AG (FSE:EVT) to €16 from €5.50, reflecting a review of the company’s partnered pipeline assets. The stock was recently quoted at €11.66. Analyst...

AzurRx BioPharma

HCW starts AzurRx at buy

H.C. Wainwright initiated coverage of AzurRx BioPharma (NASDAQ:AZRX) with a “buy” rating and $8 price target. The stock closed at $4.11 on July 24. AzurRx is developing a novel recombinantly produced pancreatic lipase...

Reata Pharma

Stifel ups Reata price target to $50

Stifel raised its price target for “buy-rated” Reata Pharmaceuticals (NASDAQ:RETA) to $50 from $38 after the company reported statistically significant improvements in kidney function from the Phase 2 portion of its...

Concert Pharma

HCW starts Concert at buy

H.C. Wainwright initiated coverage of Concert Pharmaceuticals (NASDAQ:CNCE) with a “buy” rating and $20 price target. The stock closed at $16.10 on July 24. Concert’s deuteration technology is a de-risked platform for...

Dova Pharmaceuticals

Leerink starts Dova at MP

Leerink initiated coverage of Dova Pharmaceuticals (NASDAQ:DOVA) with a “market perform” rating and a $24 price target. The stock closed at $22.75 on July 21. Analyst Geoffrey Porges writes that his rating and valuation...

Mersana Therapeutics Logo

Leerink starts Mersana at OP

Leerink launched coverage of Mersana Therapeutics (NASDAQ:MRSN) with an “outperform” rating and $23 one-year price target, representing an approximate $500-million valuation. The stock closed at $14.05 on July 21...

CRH Medical

RBC upgrades CRH Medical to OP

RBC Capital Markets upgraded CRH Medical (TSX:CRH; NYSE MKT:CRHM) to “outperform” from “sector perform” but lowered its price target to $6 (Canadian) from $8.50. The stock closed at $4.07 on July 20. Analyst Doug Miehm...

Agile Therapeutics

HCW starts Agile Therapeutics at buy

H.C. Wainwright launched coverage of Agile Therapeutics (NASDAQ:AGRX) with a “buy” rating and $10 price target, saying the company is significantly undervalued assuming its Twirla combination hormonal contraceptive...

Eiger BioPharmaceuticals Logo

BTIG starts Eiger BioPharma at buy

BTIG initiated coverage of Eiger BioPharmaceuticals (NASDAQ:EIGR) with a “buy” rating and $32 price target. The stock closed at $7.45 on July 13. Eiger has four significant assets in Phase 2 clinical testing for four...